Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109837 · ClinicalTrials.gov registry record · Phase 2
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
A Phase 2 study of Leukemia, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
- 20
- Study locations
NCT00109837 is a Phase 2 study of Leukemia that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 79 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT00109837, a Phase 2 study of Leukemia, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), and giving the drugs in different combinations may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed acute lymphoblastic leukemia.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG daunorubicin
Study Locations (20)
Kansas
- Cancer Center of Kansas, PA - Chanute - Chanute
- Cancer Center of Kansas, PA - Dodge City - Dodge City
- Cancer Center of Kansas, PA - El Dorado - El Dorado
- Cancer Center of Kansas-Independence - Independence
- Cancer Center of Kansas, PA - Kingman - Kingman
- Lawrence Memorial Hospital - Lawrence
- Southwest Medical Center - Liberal
- Cancer Center of Kansas, PA - Newton - Newton
- Menorah Medical Center - Overland Park
- Cancer Center of Kansas, PA - Parsons - Parsons
- Cancer Center of Kansas, PA - Pratt - Pratt
- Cancer Center of Kansas, PA - Salina - Salina
- Shawnee Mission Medical Center - Shawnee Mission
- Cancer Center of Kansas, PA - Wellington - Wellington
- Associates in Womens Health, PA - North Review - Wichita
- Cancer Center of Kansas, PA - Medical Arts Tower - Wichita
- Cancer Center of Kansas, PA - Wichita - Wichita
- CCOP - Wichita - Wichita
California
- Providence Saint Joseph Medical Center - Burbank - Burbank
Illinois
- Cardinal Bernardin Cancer Center at Loyola University Medical Center - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2005-04 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109837
The ClinicalTrials.gov registry entry for NCT00109837 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (84% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00109837 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Kansas, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00109837 about?
NCT00109837 is a clinical study titled "S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), and giving the drugs in different combinations may kill more cancer cells. PURPOSE: T...
What is the current status of trial NCT00109837?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2005-04. Estimated completion is 2014-11.
What conditions does trial NCT00109837 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00109837?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG), daunorubicin (DRUG).
Who is sponsoring clinical trial NCT00109837?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00109837 being conducted?
This trial has 20 study locations across California, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.